Abstract
AbstractObjectiveRespiratory syncytial virus (RSV) is a common respiratory pathogen not only in children, but also in adults. Country-specific data on the epidemiology and burden of disease are essential for policy decisions. In view of a recent authorization of adult RSV vaccines, we aimed to comprehensively collect and assess evidence on the epidemiology and burden of RSV in Italian adults.MethodsA systematic literature review was conducted according to the available guidelines. Random-effects proportional meta-analysis was performed to obtain pooled estimates and the observed heterogeneity was investigated by using both subgroup and meta-regression analyses.ResultsA total of 35 studies were identified. RSV seasonal attack rates ranged from 0.8 ‰ in community-dwelling older adults to 10.9% in hematological outpatients. On average, 4.5% (95% CI: 3.2–5.9%) of respiratory samples tested positive for RSV. This positivity prevalence was higher in older adults (4.4%; 95% CI: 2.8– 6.3%) than in working-age adults (3.5%; 95% CI: 2.5–4.6%) and in outpatient (4.9%; 95% CI: 3.1–7.0%) than inpatient (2.9%; 95% CI: 1.5–4.8%) settings. Study location and sample size were also significant predictors of RSV detection frequency. The pooled estimate of in-hospital mortality was as high as 7.2% (95% CI: 4.7– 10.3%). However, other important indicators of the diseases burden, such as complication and hospitalization rates, are missing.ConclusionRSV poses a measurable burden on Italian adults, especially those of older age and with some co-morbidities. Policy makers should give priority to health technology assessment of the novel RSV vaccines.
Publisher
Cold Spring Harbor Laboratory